Streetbeat News

Earnings

CVS

CVS Health has reaffirmed its full-year 2024 GAAP guidance of at least $7.06 and adjusted EPS guidance of at least $8.30, slightly below the estimated $8.32. The company will also provide updates on recent business trends and initiatives in an upcoming webcast.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:16 am

APGE

Apogee Therapeutics reported a Q4 2023 net loss of $(31.7)M, widening from $(14)M YoY. The company ended the year with $395.5M in cash, projecting a cash runway into 4Q 2026.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:12 am

MNKD

MannKind Corporation announced new clinical data from its INHALE-3 Phase 4 study comparing inhaled insulin (plus basal) versus standard of care. The findings were presented at the International Conference on Advanced Technologies and Treatments for Diabetes.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:08 am

PODD

Insulet announced it will present results from its first Omnipod 5 Randomized Controlled Trial (OP5-003) at the International Conference on Advanced Technologies & Treatments for Diabetes. This marks a significant milestone for the company as it showcases the effectiveness and advancements of its Omnipod 5 product.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:04 am

APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE) announced positive interim Phase 1 results for APG777, a treatment for atopic dermatitis and other inflammatory diseases. The study showed promising pharmacokinetic and pharmacodynamic data, with a half-life of approximately 75 days and sustained inhibition of key biomarkers for around 3 months.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:03 am

TSLA

Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management and a Tesla investor, expressed concerns over Tesla's falling earnings despite increased sales of Cybertrucks and overall vehicles. He highlighted the need for Tesla to address the decline in earnings amidst high sales volumes. Gerber also noted that Tesla is being valued more as a hardware company due to intense competition in China and its failure to achieve autonomous driving. Tesla's stock dropped over 7% following a reported decline in vehicle sales in China for February.

Portfolio Pulse from Anan Ashraf

March 05, 2024 | 10:59 am

NIO

NIO Inc. projects its Q1 2024 revenue to range between $1.48B and $1.56B, with vehicle deliveries estimated at 31,000 to 33,000 units. This forecast suggests a slight decrease to a moderate increase in both revenue and deliveries compared to Q1 2023.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 10:07 am

NIO

NIO Inc. reported a 25.0% year-over-year increase in Q4 vehicle deliveries, totaling 50,045 units, despite a 9.7% decrease from the previous quarter. The deliveries included 33,679 premium smart electric SUVs and 16,366 sedans.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 10:04 am

NIO

NIO reported Q4 adjusted EPS of $(0.39), surpassing the $(0.51) estimate, and sales of $2.41B, exceeding the $2.29B estimate. This represents an 11.36% increase in EPS and a 3.43% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 10:03 am

ALB

CLSK

FUFU

GTLB

MARA

MSTR

SEMR

SFIX

SMCI

GitLab Inc. (GTLB) shares fell 22.4% in pre-market trading after issuing a weak earnings forecast for FY25, below analyst expectations. Other stocks such as Stitch Fix (SFIX), Semrush Holdings (SEMR), MicroStrategy (MSTR), Ethereal Tech (FUFU), CleanSpark (CLSK), Albemarle Corporation (ALB), Marathon Digital Holdings (MARA), and Super Micro Computer (SMCI) also recorded losses in pre-market trading due to various factors including disappointing financial results, proposed offerings, and market volatility.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 10:00 am